FDA approves cabozantinib for previously treated advanced neuroendocrine tumors
The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced neuroendocrine tumors, offering a new standard of care for this ...
15 hours ago
0
0